Key Developments: SafeCode Drug Technologies Corp (SAFC.OB)
0.00USD
18 Jun 2013
$-0.00 (-11.11%)
$0.00
$0.00
$0.00
$0.00
1,796,920
589,716
$0.34
$0.00
Latest Key Developments (Source: Significant Developments)
Safecode Drug Technologies Corp Announces Board Changes-Form 8-K
Safecode Drug Technologies Corp reported in its Form 8-K that on April 8 2013, the Company accepted the resignation of Joel Klopfer as President, Chief Executive Officer (CEO) and a director. Mr. Akiva Schonfled , has been appointed by the Board of Directors to also serve as the Company's interim CEO. Full Article
Safecode Drug Technologies Corp Receives Investment From Biomedix Ltd.
Safecode Drug Technologies Corp announced that Israeli's Biomedix Ltd.,, a Medical Device/Biotech incubator has agreed to fund and purchase SAFC shares at 0.15 cents per share. Biomedix currently holds $200,000 USD worth of SafeCode Drug Technologies shares on its books. Full Article
Safecode Drug Technologies Corp Announces Share Buy Back Program
Safecode Drug Technologies Corp announced that the share Buyback Program which was authorized by the Board Of Directors will commence during the month of January 2013 and is expected to last approximately one-three months. The shares will be returned to the Treasury of the Company to be used for further issuances for future acquisitions of companies or technology applications in the medical industry. Funding for the acquisition of the shares will be subject to financing from third parties. Under the program approved by the BOD, SafeCode Drug Technologies Corp is authorized to repurchase up to one million of outstanding shares of common stock at a price up to $0.20 per share on the open market. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
